Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
A Phase II Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Tumor Vaccine Administered With IL-2 in Patients With Metastatic Colorectal Cancer
Sponsor: University of Michigan
A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by University of Michigan and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan
- University of Michigan Rogel Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .